129981-36-8|Sampatrilat|(S)-3-((S)-6-amino-2-(methylsulfonamido)hexanamido)-4-(1-(((S)-1-carboxy-2-(4-hydroxyphenyl)ethyl)carbamoyl)cyclopentyl)butanoic acid|-范德生物科技公司

Sampatrilat

NMR下载 COA and HPLC MSDS下载
names：
(S)-3-((S)-6-amino-2-(methylsulfonamido)hexanamido)-4-(1-(((S)-1-carboxy-2-(4-hydroxyphenyl)ethyl)carbamoyl)cyclopentyl)butanoic acid
CAS号：
129981-36-8
MDL Number：
MF(分子式)： C26H40N4O9S MW(分子量)： 584.685
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	(S)-3-((S)-6-amino-2-(methylsulfonamido)hexanamido)-4-(1-(((S)-1-carboxy-2-(4-hydroxyphenyl)ethyl)carbamoyl)cyclopentyl)butanoic acid
英文别名	Sampatrilat; UK-81252; UK 81252; UK81252; UK-81,252; UK 81,252; UK81,252.
CAS号	129981-36-8
Inchi	InChI=1S/C26H40N4O9S/c1-40(38,39)30-20(6-2-5-13-27)23(34)28-18(15-22(32)33)16-26(11-3-4-12-26)25(37)29-21(24(35)36)14-17-7-9-19(31)10-8-17/h7-10,18,20-21,30-31H,2-6,11-16,27H2,1H3,(H,28,34)(H,29,37)(H,32,33)(H,35,36)/t18-,20+,21+/m1/s1
InchiKey	DGTDHMSPXWLPNJ-GIVPXCGWSA-N
分子式 Formula	C26H40N4O9S
分子量 Molecular Weight	584.685
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	Sampatrilat(CAS:129981-36-8):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	Sampatrilat, aslo known as UK-81252, is a NEP/ACE inhibitor potentially for the treatment of hypertension and heart failure.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Machowska A, Juszczak K, Novak P, Thor P. The natriuretic peptide neurohormonal system modulation by vasopeptidase inhibitors--the novel therapeutical approach of hypertension treatment. Folia Med Cracov. 2009;50(3-4):35-42. Review. PubMed PMID: 21853869.

[2]Chang RK, Shojaei AH. Effect of a lipoidic excipient on the absorption profile of compound UK 81252 in dogs after oral administration. J Pharm Pharm Sci. 2004 Jan 23;7(1):8-12. PubMed PMID: 15144729.

[3] Gurzu B, Costuleanu M, Petrescu G. [Alternative pathways for the activation of the renin-angiotensin system]. Rev Med Chir Soc Med Nat Iasi. 2003 Oct-Dec;107(4):710-7. Review. Romanian. PubMed PMID: 14756007.

[4] Maki T, Nasa Y, Tanonaka K, Takahashi M, Takeo S. Beneficial effects of sampatrilat, a novel vasopeptidase inhibitor, on cardiac remodeling and function of rats with chronic heart failure following left coronary artery ligation. J Pharmacol Exp Ther. 2003 Apr;305(1):97-105. PubMed PMID: 12649357.

[5] Sagnella GA. Vasopeptidase inhibitors. J Renin Angiotensin Aldosterone Syst. 2002 Jun;3(2):90-5. Review. PubMed PMID: 12228848.

6: Allikmets K. Sampatrilat Shire. Curr Opin Investig Drugs. 2002 Apr;3(4):578-81. PubMed PMID: 12090727.7: Nathisuwan S, Talbert RL. A review of vasopeptidase inhibitors: a new modality in the treatment of hypertension and chronic heart failure. Pharmacotherapy. 2002 Jan;22(1):27-42. Review. PubMed PMID: 11794428.8: Asher JR, Naftilan AJ. Vasopeptidase inhibition: a new direction in cardiovascular treatment. Curr Hypertens Rep. 2000 Aug;2(4):384-91. Review. PubMed PMID: 10981174.9: Sampatrilat. UK 81252. Drugs R D. 1999 Apr;1(4):352-3. PubMed PMID: 10566063.10: Norton GR, Woodiwiss AJ, Hartford C, Trifunovic B, Middlemost S, Lee A, Allen MJ. Sustained antihypertensive actions of a dual angiotensin-converting enzyme neutral endopeptidase inhibitor, sampatrilat, in black hypertensive subjects. Am J Hypertens. 1999 Jun;12(6):563-71. PubMed PMID: 10371365.1

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开